Executive summary

- Novavax has a prefusion, stable and highly immunogenic recombinant SARS-CoV-2 Spike protein nanoparticle vaccine candidate (NVX-CoV2373)
- Novavax is employing a mature vaccine platform to address the current COVID-19 pandemic
- NVX-CoV2373 can be scaled up to deliver 100M doses by year end and >1 billion doses in 2021
- NVX-CoV2373 could potentially be deployed by the end of 2020
- Funded by CEPI

Novavax, Inc. (U.S.)
Novavax AB (Sweden)

NVX-CoV2373 binds with high affinity to hACE2 receptor

Binding is an indication of the correct prefusion structure, predicts induction of functional antibodies that will block infection
Developing COVID-19 Vaccines in Record Time

NAISS – 5/12/2020

NVX-CoV2373+Matrix-M Baboons
Anti-S IgG, hACE2 receptor inhibition, and Neutralization

NVX-CoV2373 phase 1 clinical trial
With or without 50 mg Matrix M™ adjuvant

• Single protocol Phase 1/Phase 2
  • Phase 1 – 130 subjects, 18-59 years of age
    • ELISA, Receptor Binding Inhibition
    • Neutralisation, CMRI – Th1/Th2
  • Phase 2 to follow closely on day 35 Phase 1 results
  • ~2200 Subjects, 1000 > Older Adults
  • Additional dose finding
  • COVID-19 disease endpoints – PCR confirmed
  • Trigger for Phase 3 (or potential EUA)
  • Other parallel trials in other geographies and populations

*Mainframe, UVMD School of Medicine BSL3 SARS-Cov-2 virus infection vero E6 cell CPE (EMVI) assay.